GlobeNewswire

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
14/10/2026
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
14/10/2026
Dr. O’Malley brings deep immunology clinical development expertise, with previous leadership roles at CRISPR Therapeutics and Sanofi Appointment follows Matchpoint’s recent $150M Series B financing to advance pipeline [...]
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
14/10/2026
FDA’s Rare Disease Evidence Principles ( RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance enables engagement with [...]
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
14/10/2026
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate [...]
Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise
14/10/2026
- Proprietary siRNA platforms, designed to enable robust and durable gene silencing throughout the brain, support a differentiated Huntington’s disease franchise and broader neurological disease pipeline focused on [...]
Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients
14/10/2026
- Phase 2-Ready EL777 Complements Company’s Turletricin Program Focused on Early Antifungal Treatment - Prophylaxis Is Critical for Cancer and Transplant Patients at High Risk of Invasive Fungal Infections BOSTON, Oct. [...]
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
14/10/2026
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC- [...]
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
14/10/2026
ALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
14/10/2026
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S. Patient [...]
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
14/10/2026
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies Expands access to a potential one- [...]
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
14/10/2026
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe [...]
Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
14/10/2026
Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional cost VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE [...]
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
14/10/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property [...]
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
14/10/2026
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing [...]
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
14/10/2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
14/10/2026
PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes ( [...]
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
14/10/2026
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule [...]
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
14/10/2026
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics [...]
The MUHC Foundation launches the Women’s Health Circle to accelerate progress in women’s health
14/10/2026
A new philanthropic movement is bringing together 500 women to advance research and care in women’s health, building on strong early support and six transformative projects already underway MONTREAL, Oct. 14, 2026 ( [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum